Drug Design, Development and Therapy

Beyond Monoclonal Antibodies: Cutting-Edge Approaches to Targeted Therapy

Monoclonal antibodies have revolutionized the development of targeted therapies, enabling the precise and selective targeting of disease biomarkers, leading to the development of more effective therapies. While over 100 monoclonal antibodies have been approved by the FDA, recent advancements in molecular engineering have greatly expanded the array of engineered proteins that have been approved by regulatory bodies or are currently being evaluated in clinical trials. As a result, the development of targeted therapies has become more versatile and sophisticated, offering new hope for patients with previously untreatable diseases. This Article Collection highlights the latest advancements in antibody and protein engineering, including design strategies, preclinical screening methods and their translation into clinical practice.